Clinical Trials · NCT00461149
Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Federico II University
- Enrollment
- 50
- Start date
- Jan 1995
- Locations
- 1 site, Italy
- Primary endpoint
- GH and IGF-I control